Latest Strategy News

Beonic Limited reported a 5.5% revenue increase to $11.2 million and reduced its net loss to $1.44 million for the half-year ending December 2025. The company also repaid a $4.65 million loan and secured a major $7.3 million contract to deploy passenger flow management solutions across seven Moroccan airports.

Duxton Farms Limited reported a significant half-year loss driven by acquisition and integration costs following a major portfolio expansion. The company is navigating a strategic shift towards diversified agriculture with plans to stabilise earnings over the coming years.

Lowell Resources Fund reported a remarkable 63% increase in net asset value for the half-year ending December 2025, driven by a strategic overweight in gold equities and buoyed by soaring commodity prices.

US Masters Residential Property Group reported a $57.3 million net loss for 2025 amid a strategic shift to wind down operations by selling its entire US residential property portfolio by the end of 2026. The Group surpassed its aggressive 2025 sales target, setting the stage for capital returns to security holders.

CVC Limited has finalized the unconditional sale of its Laverton property through a joint venture, forecasting a significant profit and strong cash inflow for FY 2026.

LDR Capital Property Fund has locked in a lease renewal with the Commonwealth Government at Garema Court, extending tenancy to 2030 and significantly reducing near-term leasing risk.

MCS Services Limited has finalized a revised agreement to sell the core assets of its subsidiary Highways Traffic Pty Ltd to Altus Traffic for $1.16 million, pending shareholder approval. This marks a strategic step in MCS’s ongoing business realignment following the sale of its larger security division.

Merino & Co. has landed a significant A$300,000 domestic purchase order, marking a key step in its strategy to rebuild and strengthen its Australian wholesale channels while balancing international growth.

Advanced Braking Technology Ltd has corrected its half-year results to reveal a robust 55.2% increase in earnings per share, alongside a strong 27% revenue growth driven by demand for its safety braking systems.

Percheron Therapeutics reports a 64% reduction in half-year losses to $3.1 million, driven by progress in its licensed immuno-oncology drug HMBD-002 and a strategic pivot away from discontinued assets.

Pengana Global Private Credit Trust reported a robust half-year performance with $7.5 million net profit and a stable NAV of $2.00 per unit, supported by a $69 million capital raise and an 8.9% annual yield. Despite increased market volatility, the Trust’s diversified private credit portfolio remains resilient.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.